Table 2. Time-to-event outcomes in VeriStrat- and treatment-defined groups of patients.
|
PFS |
OS |
|||||
|---|---|---|---|---|---|---|
| Patient groups | Median (95% CI), month | HR (95% CI) | Log-rank P | Median (95% CI), month | HR (95% CI) | Log-rank P |
| VSG | 6.5 (3.9–8.8) | 0.36a (0.22–0.61) | <0.0001 | 10.8 (7.8–17.7) | 0.26a (0.15–0.47) | <0.0001 |
| VSP | 1.6 (1.1–2.5) | 3.4 (2.4–4.3) | ||||
| VSG Carbo/Pem | 3.8 (2.7–8.7) | 0.30a (0.14–0.62) | 0.0007 | 9.4 (5.0–15.3) | 0.26a (0.12–0.55) | 0.0002 |
| VSP Carbo/Pem | 1.6 (1.0–2.5) | 3.4 (1.0–4.3) | ||||
| VSG Cis/Pem | 7.9 (5.2–13.1) | 0.39a (0.18–0.85) | 0.0141 | 17.7 (9.9–24.9) | 0.25a (0.10–0.62) | 0.0013 |
| VSP Cis/Pem | 1.7 (1.1–3.9) | 4.2 (2.6–8.9) | ||||
| Carbo/Pem | 2.8 (2.0–4.0) | 1.59b (0.97–2.61) | 0.0627 | 6.0 (4.2–10.0) | 1.64b (0.96–2.82) | 0.0701 |
| Cis/Pem | 5.7 (3.8–8.8) | 10.3 (6.6–17.9) | ||||
Abbreviations: CI=confidence interval; Carbo=carboplatin; Cis=cisplatin; HR=hazard ratio; N/R=not reached; OS=overall survival; Pem=pemetrexed; PFS=progression-free survival; VSG=VeriStrat Good; VSP=VeriStrat Poor.
a
HR calculated for VeriStrat Good vs VeriStrat Poor using unadjusted Cox proportional hazard model.
b
HR calculated for Carbo/Pem vs Cis/Pem using unadjusted Cox proportional hazard model.